Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke

Author： Ringleb Peter A   Schwark Christian   Schwaninger Markus   Schellinger Peter D  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.3, 2005-03, pp. : 359-367

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Value of antiplatelets in the spotlight for secondary prevention

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 543, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Value of antiplatelets in the spotlight for secondary prevention

By  

Inpharma, Vol. 1, Iss. 1618, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox ® /Asasantin ® ) in France

By Jean-Pierre Marissal   Bernard Selke  

PharmacoEconomics, Vol. 22, Iss. 10, 2004-01 ,pp. : 661-670

Adis International

Access to resources Recommend Favorite

Pharmacotherapy for the Secondary Prevention of Stroke

By Toyoda Kazunori  

Drugs, Vol. 69, Iss. 6, 2009-01 ,pp. : 633-647

Adis International

Access to resources Recommend Favorite

Clopidogrel for the secondary prevention of stroke

By Diener Hans-Christoph   Ringleb Peter A   Savi Pierre  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 5, 2005-05 ,pp. : 755-764

Informa Healthcare

Access to resources Recommend Favorite